研報掘金丨國海證券:片仔癀三季度利潤重拾增長,首予“買入”評級
國海證券研報指出,片仔癀(600436.SH)2024年三季度利潤重拾增長,渠道擴張持續推進。Q3公司營業收入28.00億元(yoy+9.60%),歸母淨利潤9.65億元(yoy+11.73%)。公司肝病用藥2024年Q3毛利率為68.23%,環比提升0.28pct,基本穩定。此外,在2024年9月21日,片仔癀主辦了王琦領銜的院士專家工作站專題研討會,共話“中藥新藥研發、創新與轉化”。公司與各品牌連鎖進行了2024 年老字號臻選專區項目的簽約儀式和全品類戰略合作啟動。該行認為公司核心產品片仔癀銷量穩健增長,產品梯隊不斷豐富,推動公司業績長期向好。首次覆蓋,給予“買入”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.